Duopharma Biotech Bhd 2024 IR
The report outlines Duopharma Biotech Berhad's financial and sustainability performance for the fiscal year 2024. Key achievements include a 15.5% increase in revenue to RM813.70 million and the successful installation of solar panels across all manufacturing sites, avoiding 1,839 tCO2e of carbon emissions. Additionally, the company's erythropoietin product, ERYSAA, became the first biosimilar to receive halal certification from JAKIM. The company also established its Nature and Biodiversity Policy and became the first Malaysian company to sign the UN Global Compact Forward Faster for Water Resilience initiative.
Company: Duopharma Biotech Bhd
Sector: Health Care
Country: Malaysia
Year: 2024
Type: IR
Pages: 248
Duopharma Biotech Bhd
Integrated Annual Report
The report outlines Duopharma Biotech Berhad's financial and sustainability performance for the fiscal year 2024. Key achievements include a 15.5% increase in revenue to RM813.70 million and the successful installation of solar panels across all manufacturing sites, avoiding 1,839 tCO2e of carbon emissions. Additionally, the company's erythropoietin product, ERYSAA, became the first biosimilar to receive halal certification from JAKIM. The company also established its Nature and Biodiversity Policy and became the first Malaysian company to sign the UN Global Compact Forward Faster for Water Resilience initiative.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
May 21, 2025
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees